Moving the needle: strengthening ethical protections for people who inject drugs in clinical trials

Those researching HIV prevention measures for people who inject drugs (PWID) face a dilemma. Regions where baseline HIV prevalence and onward transmission via injecting is sufficiently high to power HIV prevention trials are also those where repressive laws, policies and practices raise concerns abo...

Full description

Saved in:  
Bibliographic Details
Main Author: Wolfe, Daniel (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2018
In: Journal of medical ethics
Year: 2018, Volume: 44, Issue: 3, Pages: 161-162
Online Access: Volltext (JSTOR)
Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000caa a22000002 4500
001 1816157430
003 DE-627
005 20230428063455.0
007 cr uuu---uuuuu
008 220908s2018 xx |||||o 00| ||eng c
024 7 |a 10.1136/medethics-2016-103572  |2 doi 
035 |a (DE-627)1816157430 
035 |a (DE-599)KXP1816157430 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Wolfe, Daniel  |e VerfasserIn  |4 aut 
245 1 0 |a Moving the needle: strengthening ethical protections for people who inject drugs in clinical trials 
264 1 |c 2018 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Those researching HIV prevention measures for people who inject drugs (PWID) face a dilemma. Regions where baseline HIV prevalence and onward transmission via injecting is sufficiently high to power HIV prevention trials are also those where repressive laws, policies and practices raise concerns about the ethics of research subject protection. Dawson et al, outlining criteria to address ethical challenges in HIV prevention research among PWID, recommend that all trial participants be offered sterile injecting equipment and urge additional strategies to limit research and background risks.1 In light of ethical questions opened by recent clinical trials involving PWID, including several the authors cite favourably, these cautions are timely.Dawson et al urge weighing of costs and benefits of PWID participation in research trials as an essential part of the ethical calculus. Overdose is a particular risk in any trial that uses abstinence from opioids as a precondition for participation or as an outcome of interest, and a risk that institutional review boards and researchers frequently ignore. Given the increased likelihood of fatal overdose for those who return to injection following a period of abstinence, provision to all trial participants of naloxone—the overdose antidote … 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 44(2018), 3, Seite 161-162  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:44  |g year:2018  |g number:3  |g pages:161-162 
856 |3 Volltext  |u http://www.jstor.org/stable/26879686  |x JSTOR 
856 4 0 |u https://doi.org/10.1136/medethics-2016-103572  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/44/3/161.abstract  |x Verlag  |z lizenzpflichtig  |3 Volltext 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4185611374 
LOK |0 003 DE-627 
LOK |0 004 1816157430 
LOK |0 005 20220908053719 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-03#AF8D3F300D13A10734ECAD54C8B07779E5E7B916 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 866   |x JSTOR#http://www.jstor.org/stable/26879686 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1  |b inherited from superior work 
ORI |a SA-MARC-ixtheoa001.raw